APA (7th ed.) Citation

O, L. S., M, A., J, B., S, B., M, B., J, C., . . . I, R. (2024). Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature communications, 15(1), 5932. https://doi.org/10.1038/s41467-024-47000-5

Chicago Style (17th ed.) Citation

O, Le Saux, et al. "Immunomic Longitudinal Profiling of the NeoPembrOv Trial Identifies Drivers of Immunoresistance in High-grade Ovarian Carcinoma." Nature Communications 15, no. 1 (2024): 5932. https://doi.org/10.1038/s41467-024-47000-5.

MLA (9th ed.) Citation

O, Le Saux, et al. "Immunomic Longitudinal Profiling of the NeoPembrOv Trial Identifies Drivers of Immunoresistance in High-grade Ovarian Carcinoma." Nature Communications, vol. 15, no. 1, 2024, p. 5932, https://doi.org/10.1038/s41467-024-47000-5.